keyword
MENU ▼
Read by QxMD icon Read
search

extended thromboprophylaxis

keyword
https://www.readbyqxmd.com/read/29715571/length-of-thromboprophylaxis-in-patients-operated-for-a-high-grade-glioma-a-retrospective-study
#1
Joeky T Senders, Tom J Snijders, Max van Essen, Gaby M van Bentum, Tatjana Seute, Filip Y de Vos, Timothy R Smith, Pierre A Robe, Marike Ld Broekman
OBJECTIVE: High-grade gliomas are associated with venous thromboembolism (VTE). This retrospective study with a parallel cohort design investigates the influence of continuing prophylactic anticoagulation post-discharge on the rate of VTE and intracranial hemorrhage (ICH) in patients operated for a high-grade glioma. METHODS: Consecutive adult patients who underwent sub- or gross-total resection for a high-grade glioma at a single institution were included. Multivariable logistic regression analysis was used to investigate the association between the duration of thromboprophylaxis (dalteparin administered 21 versus 0-7 days) and the occurrence of VTE and ICH within 21 or 90 days after surgery, corrected for known risk factors...
April 28, 2018: World Neurosurgery
https://www.readbyqxmd.com/read/29703469/prothrombotic-genotypes-and-risk-of-venous-thromboembolism-in-cancer
#2
Olga V Gran, Sigrid K Brækkan, John-Bjarne Hansen
Venous thromboembolism (VTE) is a common and potentially life-threatening complication in cancer. Patients with cancer are at a higher risk of VTE-related complications such as major bleeding during anticoagulant treatment, recurrence and mortality. Therefore, it is important to identify cancer patients with high risk of VTE in order to implement targeted prevention to those with a favorable benefit-to-harm ratio for thromboprophylaxis. VTE is strongly heritable, and during the last decades, several prothrombotic genotypes associated with VTE-risk have been identified...
April 2018: Thrombosis Research
https://www.readbyqxmd.com/read/29645005/ongoing-efforts-to-reduce-perioperative-morbidity-of-radical-cystectomy-towards-widespread-adoption-of-extended-duration-thromboprophylaxis
#3
EDITORIAL
Vignesh T Packiam, Joseph J Pariser
No abstract text is available yet for this article.
March 2018: Translational Andrology and Urology
https://www.readbyqxmd.com/read/29594815/has-time-come-for-the-use-of-direct-oral-anticoagulants-in-the-extended-prophylaxis-of-venous-thromboembolism-in-acutely-ill-medical-patients-no
#4
Francesco Marongiu, Doris Barcellona
Acutely ill hospitalized medical patients are at high risk of venous thromboembolism (VTE). Although thromboprophylaxis in these patients is recommended since 2004 by the American College of Chest Physicians, it is widely underused. The doubt as to whether or not to treat patients at high VTE risk after hospital discharge came from the knowledge that this risk may persist after the hospital admission period. Two meta-analyses comparing extended- versus short-duration prophylaxis are published. The results demonstrate an unfavorable balance between VTE prevention and incidence of major bleeding in patients assigned to extended-duration thromboprophylaxis...
March 28, 2018: Internal and Emergency Medicine
https://www.readbyqxmd.com/read/29503590/direct-oral-anticoagulants-for-extended-thromboprophylaxis-in-medically-ill-patients-meta-analysis-and-risk-benefit-assessment
#5
Majed S Al Yami, Sawsan Kurdi, Ivo Abraham
Background: Standard-duration (7-10 days) thromboprophylaxis with low molecular weight heparin, low dose unfractionated heparin, or fondaparinux in hospitalized medically ill patients is associated with ~50% reduction in venous thromboembolism (VTE) risk. However, these patients remain at high risk for VTE post-discharge. The direct oral anticoagulants (DOACs) apixaban, rivaroxaban and betrixaban have been evaluated for extended-duration (30-42 days) thromboprophylaxis in this population...
2018: Journal of Blood Medicine
https://www.readbyqxmd.com/read/29502768/new-trends-in-anticoagulation-therapy
#6
REVIEW
Margaret Smith, Glenn Wakam, Thomas Wakefield, Andrea Obi
Anticoagulation pharmacy has been dramatically altered with US Food and Drug Administration (FDA) approval of 5 direct oral anticoagulants, 1 novel reversal agent and, a second designated for fast-track approval. Trial data surrounding current trends in anticoagulant choice for VTE, reversal, and bridging are constantly redefining practice. Extended therapy for unprovoked VTE has expanded to include low-dose direct oral anticoagulants, aspirin, and the use of the HERDOO2 system to identify women who can stop anticoagulant therapy without increased risk of recurrent VTE...
April 2018: Surgical Clinics of North America
https://www.readbyqxmd.com/read/29472105/identification-of-patients-at-high-risk-for-post-discharge-venous-thromboembolism-after-hepato-pancreato-biliary-surgery-which-patients-benefit-from-extended-thromboprophylaxis
#7
Eliza W Beal, Dmitry Tumin, Jeffery Chakedis, Erica Porter, Dimitrios Moris, Xu-Feng Zhang, Sherif Abdel-Misih, Mary Dillhoff, Andrei Manilchuk, Jordan Cloyd, Carl R Schmidt, Timothy M Pawlik
BACKGROUND: The objective of the current study was to define risk factors associated with the 30-day post-operative risk of VTE after HPB surgery and create a model to identify patients at highest risk of post-discharge VTE. METHODS: Patients who underwent hepatectomy or pancreatectomy in the ACS-NSQIP Participant Use Files 2011-2015 were identified. Logistic regression modeling was used; a model to predict post-discharge VTE was developed. Model discrimination was tested using area under the curve (AUC)...
February 19, 2018: HPB: the Official Journal of the International Hepato Pancreato Biliary Association
https://www.readbyqxmd.com/read/29361459/extended-use-of-bemiparin-as-thromboprophylaxis-during-bariatric-surgery-results-of-anti-factor-xa-activity-measurements
#8
Virginia Muñoz-Atienza, Aurora Gil-Rendo, Mariano Amo-Salas, Paloma Núñez-Guerrero, Jesús Martín-Fernández
BACKGROUND: The incidence of venous thromboembolism (VTE) in morbidly obese patients after obesity surgery is between .2% and 3.5%. Because there are a lack of prospective studies on the type of drug, the correct dosage, and the optimal duration, there are no specific recommendations found in the guidelines on thrombophylaxis. OBJECTIVES: To compare the incidence of VTE and hemorrhagic events in bariatric surgical patients receiving bemiparin thromboprophylaxis who have prophylactic and nonprophylactic Anti-factor Xa (AFXa) levels...
March 2018: Surgery for Obesity and related Diseases: Official Journal of the American Society for Bariatric Surgery
https://www.readbyqxmd.com/read/29338293/betrixaban-a-new-oral-factor-xa-inhibitor-for-extended-venous-thromboembolism-prophylaxis-in-high-risk-hospitalized-patients
#9
Scott G Garland, Christina E DeRemer, Steven M Smith, John G Gums
OBJECTIVE: To review the pharmacology, pharmacokinetics, efficacy, and safety of the factor Xa (FXa) inhibitor betrixaban for extended-duration prophylaxis of acute medically ill patients with venous thromboembolism (VTE) risk factors. DATA SOURCES: A MEDLINE/PubMed (January 1990 to October 2017) search was conducted using the following keywords: betrixaban, PRT054021, FXa inhibitor, novel oral anticoagulant, NOAC, direct oral anticoagulant, DOAC, and target specific oral anticoagulant, TSOAC...
January 1, 2018: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/29302726/which-patients-require-extended-thromboprophylaxis-after-colectomy-modeling-risk-and-assessing-indications-for-post-discharge-pharmacoprophylaxis
#10
Eliza W Beal, Dmitry Tumin, Jeffery Chakedis, Erica Porter, Dimitrios Moris, Xu-Feng Zhang, Mark Arnold, Alan Harzman, Syed Husain, Carl R Schmidt, Timothy M Pawlik
BACKGROUND: Given the conflicting nature of reported risk factors for post-discharge venous thromboembolism (VTE) and unclear guidelines for post-discharge pharmacoprophylaxis, we sought to determine risk factors for 30-day post-discharge VTE after colectomy to predict which patients will benefit from post-discharge pharmacoprophylaxis. METHODS: Patients who underwent colectomy in the American College of Surgeons National Surgical Quality Improvement Project Participant Use Files from 2011 to 2015 were identified...
January 4, 2018: World Journal of Surgery
https://www.readbyqxmd.com/read/29244199/secondary-prevention-of-recurrent-venous-thromboembolism-after-initial-oral-anticoagulation-therapy-in-patients-with-unprovoked-venous-thromboembolism
#11
REVIEW
Lindsay Robertson, Su Ern Yeoh, Ahmad Ramli
BACKGROUND: Currently, little evidence is available on the length and type of anticoagulation used for extended treatment for prevention of recurrent venous thromboembolism (VTE) in patients with unprovoked VTE who have completed initial oral anticoagulation therapy. OBJECTIVES: To compare the efficacy and safety of available oral therapeutic options (aspirin, warfarin, direct oral anticoagulants (DOACs)) for extended thromboprophylaxis in adults with a first unprovoked VTE, to prevent VTE recurrence after completion of an acceptable initial oral anticoagulant treatment period, as defined in individual studies...
December 15, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29226697/update-on-the-use-of-direct-oral-anticoagulants-for-the-prevention-and-treatment-of-thromboembolism
#12
Anna Jacobs, Rajesh Kabra, Pranab Das, Carrie S Oliphant
Following publication of our review article 4 years ago, there has been an uptake in the use of nonvitamin K oral antagonists, also known as direct oral anticoagulants. The most recent Xa inhibitors to receive approval are edoxaban, which has been approved for use in both atrial fibrillation and venous thromboembolism prevention and betrixaban, which has been approved in the USA for extended thromboprophylaxis in the medically ill population. Additional analyses of certain types of atrial fibrillation patients have now become available...
January 2018: Future Cardiology
https://www.readbyqxmd.com/read/29171776/extended-thromboprophylaxis-in-the-acutely-ill-medical-patient-after-hospitalization-a-paradigm-shift-in-post-discharge-thromboprophylaxis
#13
REVIEW
Charles E Mahan, Allison E Burnett, Meghan L Fletcher, Alex C Spyropoulos
Venous thromboembolism (VTE) is a significant healthcare burden with approximately 900,000 events annually in the United States, over half of which are healthcare-associated. This number is anticipated to double by 2050. Group prophylaxis strategies confined to the inpatient setting appear to have minimal impact on the reduction of post-discharge VTE in medically ill patients due to shortened lengths of stay and a heterogenous population that includes patients at low risk for VTE. In accordance with current guideline recommendations, very few (<5%) medically ill patients are discharged with extended prophylaxis, which potentially creates a clinical gap for at-risk patients as VTE risk has been shown to persist for up to 90 days...
February 2018: Hospital Practice (Minneapolis)
https://www.readbyqxmd.com/read/29127473/colorectal-cancer-and-thrombosis
#14
P A Rees, H W Clouston, S Duff, C C Kirwan
SIGNIFICANCE: Colorectal cancer (CRC), results in a hypercoagulable state which manifests clinically as venous thromboembolism (VTE), often presenting as a deep vein thrombosis (DVT) or pulmonary embolism (PE). The consequences of VTE in CRC can be devastating, resulting in long-term morbidity and are a frequent cause of death, even amongst those who would have otherwise had a favourable cancer prognosis. The incidence of VTE in all cancers is increasing, whilst the exact incidence of VTE in CRC is likely to be underestimated...
January 2018: International Journal of Colorectal Disease
https://www.readbyqxmd.com/read/29112544/european-guidelines-on-perioperative-venous-thromboembolism-prophylaxis-day-surgery-and-fast-track-surgery
#15
Linas Venclauskas, Juan V Llau, Jean-Yves Jenny, Per Kjaersgaard-Andersen, Øivind Jans
: In recent years, day surgery and fast-track surgery have experienced a continuous increase in volume. Many procedures are now performed on an outpatient protocol, including general, orthopaedic, oncological, reconstructive or vascular surgery. The management of these patients is safe, but the incidence of venous thromboembolism in this population remains unknown. Several risk factors can be identified and stratified derived from studies of inpatient surgical management (e.g. Caprini score). Recommendations for thromboprophylaxis should be tailored from the assessment of both personal and procedure-related risk factors, although with a lack of evidence for application in outpatient management...
February 2018: European Journal of Anaesthesiology
https://www.readbyqxmd.com/read/29104003/assessment-of-the-procoagulant-potential-after-laparoscopic-sleeve-gastrectomy-a-potential-role-for-extended-thromboprophylaxis
#16
Amihai Rottenstreich, Ram Elazary, Jonathan B Yuval, Galia Spectre, Geffen Kleinstern, Yosef Kalish
BACKGROUND: Bariatric surgery is associated with increased thromboembolic risk, which may extend well beyond hospital stay. The hemostatic mechanisms implicated in this risk are not well established. OBJECTIVES: We aimed to determine the dynamics of hemostatic changes and procoagulant potential among patients undergoing laparoscopic sleeve gastrectomy, during both the early and late postoperative periods. SETTING: A university hospital. METHODS: Patients who underwent laparoscopic sleeve gastrectomy were recruited consecutively to this study...
January 2018: Surgery for Obesity and related Diseases: Official Journal of the American Society for Bariatric Surgery
https://www.readbyqxmd.com/read/29037351/rivaroxaban-versus-fondaparinux-for-thromboprophylaxis-after-endovenous-laser-ablation
#17
Hong H Keo, Frederic Baumann, Nicolas Diehm, Christian Regli, Daniel Staub
OBJECTIVE: Endovenous heat-induced thrombosis (EHIT) and deep venous thrombosis (DVT) are well-known complications after superficial endovenous thermoablation. We investigated the efficacy of rivaroxaban in preventing EHIT and DVT after endovenous laser ablation (EVLA). METHODS: We retrospectively analyzed a consecutive series of patients presenting with truncal varicosis class C2 to C6 undergoing EVLA. After EVLA, all patients received oral rivaroxaban (10 mg) or subcutaneous fondaparinux (2...
November 2017: Journal of Vascular Surgery. Venous and Lymphatic Disorders
https://www.readbyqxmd.com/read/28928880/in-surgical-colon-cancer-patients-extended-duration-thromboprophylaxis-30-days-with-the-highest-dose-of-tinzaparin-4-500-iu-s-c-q-d-normalizes-the-postoperative-vegf-levels
#18
Michail Mitsis, Panagiotis Koliou, Christina Bali, Evangelia Ntounousi, Vasileios Tatsis, Vasileios Nousias, Georgios D Lianos, Georgios Vartholomatos, Dimitrios Nastos
Background/Purpose: In colon cancer (CC) patients preoperative (pre-op) levels of VEGF-A165 (VEGF) is a strong predictor for disease recurrence. Elevated postoperative (post-op) VEGF levels could have undesirable effects by enhancing tumor growth and metastasis formation. It has been suggested that thromboprophylaxis with a Low Molecular Weight Heparin (LMWH) in surgical cancer patients, further to thromboembolic protection, may exert some anti-neoplastic properties, as well. The aim of our study was to assess the potential impact of the LMWH Tinzaparin (Innohep® - Leo Pharma, Copenhagen, Denmark), given at different doses and for different perioperative (peri-op) periods, upon the post-op variability of serum VEGF levels in surgical CC patients...
2017: Journal of Cancer
https://www.readbyqxmd.com/read/28905172/n-terminal-pro-b-type-natriuretic-peptide-and-the-risk-of-stroke-among-patients-hospitalized-with-acute-heart-failure-an-apex-trial-substudy
#19
Gerald Chi, James L Januzzi, Serge Korjian, Yazan Daaboul, Samuel Z Goldhaber, Adrian F Hernandez, Russell D Hull, Alex Gold, Alexander T Cohen, Robert A Harrington, C Michael Gibson
BACKGROUND: Among patients hospitalized with acute heart failure (HF), the prognostic value of N-terminal pro-B-type natriuretic peptide (NT-proBNP) in short-term stroke prediction remains unclear. METHODS: In the APEX trial, 7513 patients hospitalized for an acute medical illness were randomized to receive either extended-duration betrixaban (80 mg once daily for 35-42 days) or standard-of-care enoxaparin (40 mg once daily for 10 ± 4 days) for venous thromboprophylaxis...
November 2017: Journal of Thrombosis and Thrombolysis
https://www.readbyqxmd.com/read/28846822/extended-pharmacologic-thromboprophylaxis-in-oncologic-liver-surgery-is-safe-and-effective
#20
B J Kim, R W Day, C H Davis, N Narula, M H Kroll, C W D Tzeng, T A Aloia
Essentials The risk for venous thromboembolism after liver surgery remains high in the modern era. We evaluated the safety/efficacy of extended anticoagulation in liver surgery. This protocol reports zero venous thromboembolism events in 124 liver surgery patients. Extended anticoagulation after oncologic liver surgery is safe and effective. SUMMARY: Background The incidence of venous thromboembolism (VTE) after liver surgery remains high. Objective To evaluate the safety and efficacy of extended pharmacologic thromboprophylaxis after liver surgery for the prevention of VTE...
November 2017: Journal of Thrombosis and Haemostasis: JTH
keyword
keyword
105554
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"